10-Q: Globus Medical Q3 Earnings Surge on Nevro Merger

Globus Medical reported a significant increase in net income and sales for the third quarter and first nine months of 2025, largely driven by the Nevro merger and robust Musculoskeletal Solutions performance.

Summary

• Net sales for Q3 2025 increased by 22.9% to $769.0 million, and by 13.5% to $2.11 billion for the nine months ended September 30, 2025, compared to the prior year periods.
• Net income for Q3 2025 surged to $119.0 million ($0.88 diluted EPS) from $51.8 million ($0.38 diluted EPS) in Q3 2024.
• Year-to-date net income reached $397.3 million ($2.90 diluted EPS) compared to $76.5 million ($0.56 diluted EPS) in the prior year.
• The Nevro merger, completed on April 3, 2025, contributed $193.8 million in revenue and resulted in a $114.4 million bargain purchase gain for the nine-month period.
• Musculoskeletal Solutions sales increased significantly, while Enabling Technologies sales saw a decrease due to lower unit placement.
• The company paid off $450.0 million in Senior Convertible Notes due 2025 on March 15, 2025.
• The share repurchase program was expanded by an additional $500.0 million on May 15, 2025, with $255.5 million in repurchases year-to-date.
• A $29.4 million liability was recorded for the Pimenta litigation following a jury verdict against NuVasive on November 4, 2025.

Sentiment

Score: 8

Explanation: The company reported strong financial performance with significant increases in net sales and net income, driven by the Nevro merger and Musculoskeletal Solutions. The repayment of convertible notes and expanded share repurchase program are positive. However, the decline in Enabling Technologies sales and the Pimenta litigation liability introduce some caution.

Positives

• Significant increase in net sales for both the three-month (22.9% to $769.0 million) and nine-month (13.5% to $2.11 billion) periods ended September 30, 2025.
• Substantial growth in net income for Q3 2025 (up 129.5% to $119.0 million) and YTD 2025 (up 419.5% to $397.3 million).
• Operating income for Q3 2025 increased by 185.6% to $137.4 million, and YTD 2025 increased by 193.7% to $310.5 million.
• The Nevro merger generated a $114.4 million bargain purchase gain, primarily due to deferred tax assets.
• Strong performance in Musculoskeletal Solutions, with sales increasing by $131.7 million domestically in Q3 2025, including Nevro sales.
• Repayment of $450.0 million Senior Convertible Notes due 2025, reducing debt.
• Expansion of the share repurchase program by $500.0 million, indicating confidence in future cash flows and commitment to shareholder returns.
• Net cash provided by operating activities increased by $194.6 million to $504.9 million for the nine months ended September 30, 2025.
• Restructuring costs decreased significantly by 93.1% in Q3 2025 and 41.5% YTD 2025, indicating progress in synergy and integration plans.

Negatives

• Enabling Technologies sales decreased by $9.9 million domestically in Q3 2025 and $19.6 million YTD 2025, primarily due to lower unit placement.
• Selling, general and administrative expenses increased significantly by 30.6% in Q3 2025 and 18.1% YTD 2025, partly due to Nevro expenses and the Pimenta litigation accrual.
• Acquisition-related costs increased by $18.9 million YTD 2025, primarily due to $28.8 million in Nevro Merger costs.
• Other income/(expense), net decreased by $6.1 million in Q3 2025, primarily due to foreign currency loss and lower average balance across marketable securities, cash and cash equivalents.
• Cash and cash equivalents decreased by $412.7 million for the nine months ended September 30, 2025, primarily due to debt repayment and share repurchases.
• A jury verdict of $28.7 million in damages was returned against NuVasive in the Pimenta litigation, leading to a $29.4 million liability accrual.

Risks

• Risks and costs associated with the integration of the NuVasive business and the ability to successfully integrate and achieve anticipated synergies.
• Potential impact of health epidemics, pandemics, and similar outbreaks on business operations.
• Factors affecting quarterly results, ability to manage growth, and sustain profitability.
• Challenges in maintaining demand for products and competing successfully, including convincing surgeons to use products and attracting/retaining sales personnel.
• Ability to rapidly develop and introduce new products.
• Ability to develop and execute successful business strategies.
• Compliance with changes in applicable laws and regulations.
• Ability to safeguard intellectual property.
• Success in defending legal proceedings, such as the ongoing Moskowitz Family LLC and 4WEB LLC patent infringement litigations, and the Pimenta litigation appeal.
• Trends in the medical device industry and general economic conditions.
• Future litigation or requirements to escrow funds could materially impact liquidity.
• Management excluded Nevro from its assessment of internal controls over financial reporting, which could pose a risk until fully integrated.

Future Outlook

The company expects continued growth in the U.S. market by expanding its sales force and increasing its international presence. It anticipates a continued rise in the adoption of Enabling Technologies as they become more integrated with Musculoskeletal Solutions, with new technologies like augmented reality and artificial intelligence potentially transforming surgery and improving patient outcomes. The provisions of the One Big Beautiful Bill Act (OBBBA) for accelerated depreciation and R&D expenses may reduce cash income tax expense for 2025.

Management Comments

• "Globus is committed to medical device innovation and delivering exceptional service to hospitals, ambulatory surgery centers and physicians to advance patient care and improve efficiency."
• "Since inception, Globus has listened to the voice of the surgeon to develop practical solutions and products to help surgeons effectively treat patients and improve lives."
• "We believe there is significant opportunity to strengthen our position in the U.S. market by increasing the size of our U.S. sales force and we intend to add additional direct and distributor sales representatives in the future."
• "We believe there are significant opportunities for us to increase our presence in both existing and new international markets through the continued expansion of our direct and distributor sales forces and through the commercialization of additional products."
• "As our Enabling Technologies become more fully integrated with our Musculoskeletal Solutions, a continued rise in adoption is expected."
• "We believe as new technologies such as augmented reality and artificial intelligence are introduced, Enabling Technologies have the potential to transform the way surgery is performed and most importantly, continue to improve patient outcomes."
• "Our management, including our CEO and CFO, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level."

Industry Context

The company operates in the medical device industry, specifically focusing on musculoskeletal disorders, spinal cord stimulation, and advanced surgical technologies. The market for Enabling Technologies (imaging, navigation, robotics) in spine and orthopedic surgery is described as being in its infancy, suggesting significant growth potential as these technologies become more integrated and new innovations like augmented reality and AI emerge. The company's strategy of expanding its sales force and product commercialization internationally aligns with broader industry trends of global market penetration and technological advancement in healthcare. The acquisition of Nevro Corp. further diversifies its offerings into neuromodulation for chronic pain, expanding its addressable market within musculoskeletal solutions.

Legal Proceedings

• Moskowitz Family LLC Litigation: Patent infringement suit filed on November 20, 2019, alleging willful infringement of six patents. A jury returned a defense verdict for Globus on December 14, 2023, but Moskowitz filed an appeal on September 30, 2024. The outcome is uncertain, and no liability has been recorded beyond counsel fees.
• Pimenta Litigation: Dr. Luiz Pimenta filed suit against NuVasive on April 2, 2018, for breach of contract, seeking $82 million in unpaid royalties. NuVasive filed cross-claims. On November 4, 2025, a jury returned a verdict of $28.7 million in damages against NuVasive, plus statutory interest and costs. A liability of $29.4 million (including interest accrual) has been recorded as of September 30, 2025. The company intends to vigorously defend and appeal the verdict.
• 4WEB LLC Litigation: Patent infringement suit filed against NuVasive on April 25, 2023, alleging willful infringement of eleven patents. The litigation is ongoing, and the outcome is uncertain, with no liability recorded beyond counsel fees.

Stakeholder Impact

• Shareholders: Positive impact from increased net income, EPS, and the expanded share repurchase program. Potential dilution from stock options/RSUs. Uncertainty from ongoing litigation could impact share price.
• Employees: Impacted by restructuring plans (2024 Synergy Plan and 2025 Strategic Integration Plan) which included employee termination benefits.
• Customers: Benefit from a comprehensive portfolio of innovative and differentiated technologies, including Musculoskeletal Solutions and Enabling Technologies.
• Creditors: Positive impact from the repayment of $450.0 million in Senior Convertible Notes. The company has no outstanding borrowings under its $400.0 million revolving credit facility and is in compliance with all covenants.

Next Steps

• Continue to integrate the NuVasive and Nevro businesses and achieve anticipated synergies.
• Add additional direct and distributor sales representatives to strengthen the U.S. sales force.
• Increase presence in both existing and new international markets through sales force expansion and commercialization of additional products.
• Further integrate Enabling Technologies with Musculoskeletal Solutions.
• Introduce new technologies such as augmented reality and artificial intelligence to transform surgery and improve patient outcomes.
• Vigorously defend against claims in the Pimenta litigation, including filing post-trial motions and appeals.
• Complete the final determination of fair value for certain Nevro assets and liabilities within the one-year measurement period.
• Adopt ASU No. 2023-09 (Income Taxes) in the Annual Report on Form 10-K for the year ending December 31, 2025.

Key Dates

Recommendation

The company demonstrated exceptional financial performance with substantial increases in net sales and net income, significantly exceeding prior year results. The successful integration of the Nevro merger, which also yielded a bargain purchase gain, positions the company for continued growth in Musculoskeletal Solutions. The proactive debt repayment and expanded share repurchase program signal strong financial health and a commitment to shareholder value. While there are ongoing legal proceedings and a decline in Enabling Technologies sales, the overall strategic direction, operational improvements, and robust financial metrics suggest a very positive outlook for investors.

Keywords

Musculoskeletal Solutions, Enabling Technologies, Spine Surgery, Orthopedic Trauma, Medical Devices, SEC Filing, 10-Q, Nevro Merger, Financial Results, Acquisition, Robotic Guidance, Navigation System, Neuromonitoring, Share Repurchase, Litigation, Globus Medical